MicroCoat CR - Scalable microencapsulation for prodution of oral controlled release liquid medicines

MicroCoat CR - 用于生产口服控释液体药物的可扩展微胶囊

• 批准号: 133345
• 金额: $ 13.32万
• 依托单位: FLUID PHARMA LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133345
• 关键词: MicroCoat; CR; Scalable; microencapsulation; prodution

MicroCoat technology is a pharmaceutical manufacturing process for the production of small drug particles individually surrounded by a membrane that provides a barrier to drug release. MicroCoat is used to mask the taste of drugs, to enhance the stability of medicines, and to delay the release of the active ingredients, for example when medicines irritate a patient’s stomach. MicroCoat particles are manufactured with the properties required to be stable when dispersed into liquids. Liquid medicines are easy to take by patients who have difficulty in swallowing tablets and capsules, such as children, older adults and patients with diseases that affect swallowing (e.g. stroke and Parkinson's disease). This project will develop MicroCoat CR technology as a robust manufacturing technique that can be easily scaled-up for industrial production. A new range of microparticles will be developed by carefully designing a process to coat drug particles that provides slow and steady drug release and absorption. The benefits of slow-release tablets and capsules (e.g. reduced dose frequency or side effects) will be achievable with liquid medicines. These features set MicroCoat CR apart from previous attempts to produce liquid slow release medicines and make such products a clinical reality that benefits patients.

MicroCoat技术是一种制药工艺，用于生产被膜单独包围的小药物颗粒，该膜为药物释放提供了屏障。MicroCoat用于掩盖药物的味道、增强药物的稳定性并延迟活性成分的释放，例如当药物刺激患者的胃时。MicroCoat颗粒在分散到液体中时具有稳定的特性。对于吞咽片剂和胶囊有困难的患者，如儿童、老年人和患有影响吞咽的疾病（如中风和帕金森病）的患者，液体药物易于服用。该项目将开发MicroCoat CR技术，作为一种强大的制造技术，可以很容易地扩大工业生产。通过精心设计一种包覆药物颗粒的方法，将开发出一系列新的微粒，这种药物颗粒提供缓慢而稳定的药物释放和吸收。缓释片剂和胶囊的益处（例如减少剂量频率或副作用）将通过液体药物实现。这些功能使MicroCoat CR有别于以前生产液体缓释药物的尝试，并使此类产品成为有益于患者的临床现实。